Accessibility StatementSkip Navigation ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ --Â Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVTâ"¢), with anticoagulation achieved superior reduction in right heart strain compared to nticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data was prese ...

Core Insights - Penumbra, Inc. will host an investor event on October 26, 2025, at the TCT Conference to discuss the STORM-PE clinical trial [1] - The company will also hold a conference call on November 5, 2025, to discuss its third quarter 2025 financial results [2] - Penumbra is recognized as a leading thrombectomy company, focusing on innovative technologies for medical conditions like ischemic stroke and venous thromboembolism [3] Company Events - The investor event will take place from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time [1] - A live webcast of the investor event will be available on the company's website for at least two weeks after the event [1] - The conference call for third quarter financial results will occur after market close at 4:30 PM Eastern Time [2] - A press release with the financial results will be issued after market close on the same day [2] Company Overview - Penumbra, Inc. specializes in developing technologies for challenging medical conditions, including ischemic stroke and acute limb ischemia [3] - The company's portfolio includes computer-assisted vacuum thrombectomy (CAVT) aimed at efficiently removing blood clots [3] - Penumbra supports healthcare providers in over 100 countries, focusing on improving patient outcomes and quality of life [3]